Get the Stockscreener App
0.285
2.17%
0.0049
Soligenix Inc stock is traded at $0.285, with a volume of 181.73K.
It is up +2.17% in the last 24 hours and down -74.45% over the past month.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
See More
Previous Close:
$0.2801
Open:
$0.2821
24h Volume:
181.73K
Relative Volume:
0.30
Market Cap:
$2.94M
Revenue:
$200.00K
Net Income/Loss:
$-10.95M
P/E Ratio:
-0.1444
EPS:
-1.9738
Net Cash Flow:
$-10.78M
1W Performance:
-10.03%
1M Performance:
-74.45%
6M Performance:
-78.96%
1Y Performance:
-85.36%
1-Day Range:
$0.2821
$0.289
1-Week Range:
$0.28
$0.339
52-Week Range:
$0.28
$6.2299
Soligenix Inc Stock (SNGX) Company Profile
Name
Soligenix Inc
Sector
Industry
Phone
609-538-8200
Address
29 EMMONS DRIVE, PRINCETON
Compare SNGX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNGX
Soligenix Inc
|
0.285 | 2.89M | 200.00K | -10.95M | -10.78M | -1.9738 |
VRTX
Vertex Pharmaceuticals Inc
|
439.12 | 110.45B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
714.21 | 74.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
809.12 | 50.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.18 | 38.03B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
316.62 | 32.24B | 5.36B | 287.73M | 924.18M | 2.5229 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-28-20 | Downgrade | Dawson James | Buy → Neutral |
| Jan-31-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-14-17 | Reiterated | Maxim Group | Buy |
| Jul-17-17 | Initiated | H.C. Wainwright | Buy |
Soligenix Inc Stock (SNGX) Latest News
TradingKey - TradingKey
Soligenix (SNGX) registers 1,054,688 resale shares; Q1 cash $6.03M - Stock Titan
Soligenix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
HyBryte CTCL trial halted as Soligenix (SNGX) faces going concern risk - Stock Titan
Soligenix (SNGX) Faces Setback in FLASH2 Study Results - GuruFocus
Soligenix Releases Q1 2026 Financial Results - AlphaStreet
Soligenix 1Q Loss/Shr 28c >SNGX - Moomoo
Soligenix Announces Recent Updates And First Quarter 2026 Financial Results - TradingView
Soligenix Anticipates HyBryte™ Phase 3 Results in Second Half of 2026, Reports $28.3 Million in Cash - geneonline.com
Soligenix Q1 net loss narrows on lower expenses - TradingView
Soligenix Announces Recent Updates and First Quarter 2026 Financial Results - ChartMill
SNGX stock slumps to record low after lymphoma trial fails – all eyes now on Behçet’s disease treatment - MSN
A. G. P. Maintains Soligenix(SNGX.US) With Buy Rating, Cuts Target Price to $1.5 - Moomoo
SNGX News | SOLIGENIX INC (NASDAQ:SNGX) - ChartMill
SNGX phase 3 trial halted on HyBryte - MSN
SNGX: FLASH2 Trial Recommended to Stop for Futility - Yahoo Finance
Soligenix signals pivotal year with new drug progress - Community News
Soligenix Halts FLASH2 Trial, Explores Strategic Alternatives - TipRanks
SNGX Stock Slumps To Record Low After Lymphoma Trial Fails – All Eyes Now On Behçet’s Disease Treatment - Stocktwits
SNGX Phase 3 Trial Halted on HyBryte - Yahoo Finance
Soligenix halts lymphoma drug trial after futility analysis - Investing.com UK
Disappointment in Interim Results for Soligenix (SNGX) in Phase 3 Trial - GuruFocus
Why Is Soligenix Stock Sinking Tuesday? - Benzinga
SNGX - Finviz
Soligenix halts lymphoma drug trial after futility analysis By Investing.com - Investing.com Australia
HyBryte FLASH2 failure leaves Soligenix (NASDAQ: SNGX) facing funding and pipeline risk - Stock Titan
Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma – Company AnnouncementFT.com - Financial Times
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease (PR Newswire) - Aktiellt
Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency (PR Newswire) - Aktiellt
Soligenix (SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach - NewMediaWire
Soligenix (NASDAQ: SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach - TipRanks
Soligenix (SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status - NewMediaWire
Soligenix (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status - TipRanks
Soligenix (SNGX) price target decreased by 14.29% to 15.30 - MSN
Soligenix (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results - The Globe and Mail
Soligenix (SNGX) Advances CTCL Research With Interim Analysis, Comparative Study Results - NewMediaWire
Soligenix secures EU orphan drug designation for Behçet’s disease therapy - MSN
Soligenix (NASDAQ: SNGX) Showcased for Smarter Path to Drug Development - The Globe and Mail
The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight - GlobeNewswire Inc.
Soligenix Inc Stock (SNGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.26%
4.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):